Journal of Neuro-Oncology and Neuroscience Open Access

  • ISSN: 2572-0376
  • Journal h-index: 5
  • Journal CiteScore: 0.38
  • Journal Impact Factor: 0.36
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Reach us +32 25889658

Abstract

Temozolomide Alone in Elderly GBM Patients with Poor Performance Status: Is there any Benefit?

Dulal Kiran Mondal*

GTR followed by post-op RT with concurrent TMZ followed by adjuvant TMZ is standard of care in GBM. Introduction of TMZ was based on a pivotal study in which patients were mostly 70 years or younger; increasing age was found to be a negative prognostic factor. Efficacy of this adjuvant treatment decreased with advanced age and poor performance status, as they have poor prognosis and do not tolerate this treatment well. In this population, RT alone or RT plus best supportive care or supportive care only or TMZ only tried with varied results. There is always a debate that which of these is better and should be recommended. As radiotherapy comes with the logistic problem of daily visit to hospital, we have reviewed relevant studies to see whether TMZ alone should be recommended to these patients.

Published Date: 2023-06-30; Received Date: 2021-08-09